Penumbra (PEN) Cash from Operations (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.56% |
| Dec 31, 2025 | 48.44% |
| Sep 30, 2025 | 29.63% |
| Jun 30, 2025 | -8.22% |
| Mar 31, 2025 | -4.18% |
| Dec 31, 2024 | -9.49% |
| Sep 30, 2024 | 149.73% |
| Jun 30, 2024 | -40.96% |
| Mar 31, 2024 | 5.61% |
| Dec 31, 2023 | 17.56% |
| Sep 30, 2023 | 80.38% |
| Jun 30, 2023 | 30.24% |
| Mar 31, 2023 | 881.97% |
| Dec 31, 2022 | 110.36% |
| Sep 30, 2022 | 67.38% |
| Jun 30, 2022 | -776.72% |
| Mar 31, 2022 | 51.31% |
| Dec 31, 2021 | -125.43% |
| Sep 30, 2021 | 1,201.21% |
| Jun 30, 2021 | 76.96% |
| Mar 31, 2021 | -589.77% |
| Dec 31, 2020 | 41.32% |
| Sep 30, 2020 | 83.63% |
| Jun 30, 2020 | -266.37% |
| Mar 31, 2020 | -224.19% |
| Dec 31, 2019 | -78.38% |
| Sep 30, 2019 | 1,058.70% |
| Jun 30, 2019 | 192.02% |
| Mar 31, 2019 | -127.46% |
| Dec 31, 2018 | -27.90% |
| Sep 30, 2018 | 8,323.39% |
| Jun 30, 2018 | -98.84% |
| Mar 31, 2018 | 1,280.60% |
| Dec 31, 2017 | -108.43% |
| Sep 30, 2017 | 1,554.46% |
| Jun 30, 2017 | -70.37% |
| Mar 31, 2017 | 121.18% |
| Dec 31, 2016 | -280.69% |
| Sep 30, 2016 | 193.84% |
| Jun 30, 2016 | -194.50% |
| Mar 31, 2016 | 77.73% |
| Dec 31, 2015 | -206.11% |
| Sep 30, 2015 | 46.32% |
| Jun 30, 2015 | -112.96% |
| Mar 31, 2015 | 50.67% |